HORMESIS PERVASIVENESS AND ITS POTENTIAL IMPLICATIONS FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT

被引:11
作者
Maynard, Kenneth I. [1 ]
机构
[1] Sanofi US Inc, Bridgewater, NJ 08807 USA
来源
DOSE-RESPONSE | 2011年 / 9卷 / 03期
关键词
dose response; hormesis; drug discovery; drug development; research and development; pharmaceutical industry; FOCAL CEREBRAL-ISCHEMIA; ARTERY OCCLUSION; INFARCT VOLUME; DOSE-RESPONSE; DELAYED TREATMENT; WISTAR RATS; INHIBITOR; PROTECTS; BW619C89; MODEL;
D O I
10.2203/dose-response.11-026.Maynard
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This mini-review illustrates that hormesis is not only confined to the areas of biochemistry, radiation biology and toxicology, where it is traditionally known, but illustrates, by citing published scientific literature, that it is found across a wide range of biomedical science and clinical medicine such as neuroscience, cardiology and oncology. The use of techniques and technology, including high through-put screening, micro-dosing or phase 0 studies, pharmacometrics and adaptive trial design in the clinic, are proposed to illustrate how acknowledging the potential impact of hormesis throughout different stages of drug discovery and development, including hurdles related to efficacy and safety, could help the pharmaceutical industry address some of its major and frequently mentioned challenges.
引用
收藏
页码:377 / 386
页数:10
相关论文
共 28 条
[21]   Post-treatment with nicotinamide (vitamin B3) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague-Dawley and Wistar rats [J].
Sakakibara, Y ;
Mitha, AP ;
Ogilvy, CS ;
Maynard, KI .
NEUROSCIENCE LETTERS, 2000, 281 (2-3) :111-114
[22]   Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats [J].
Sakakibara, Y ;
Mitha, AP ;
Ayoub, IA ;
Ogilvy, CS ;
Maynard, KI .
BRAIN RESEARCH, 2002, 931 (01) :68-73
[23]   The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat [J].
Schielke, GP ;
Kupina, NC ;
Boxer, PA ;
Bigge, CF ;
Welty, DF .
STROKE, 1999, 30 (07) :1472-1476
[24]   Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats [J].
Takahashi, K ;
Greenberg, JH ;
Jackson, P ;
Maclin, K ;
Zhang, J .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1997, 17 (11) :1137-1142
[25]   Neuroprotective efficacy of ebselen, an anti-oxidant with antiinflammatory actions, in a rodent model of permanent middle cerebral artery occlusion [J].
Takasago, T ;
Peters, EE ;
Graham, DI ;
Masayasu, H ;
Macrae, IM .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (06) :1251-1256
[26]   Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion [J].
Tatlisumak, T ;
Takano, K ;
Carano, RAD ;
Miller, LP ;
Foster, AC ;
Fisher, M .
STROKE, 1998, 29 (09) :1952-1958
[27]   Cerebral hemorrhage due to heparin limits its neuroprotective effects: studies in a rabbit model of photothrombotic middle cerebral artery occlusion [J].
Zhao, BQ ;
Suzuki, Y ;
Kondo, K ;
Kawano, K ;
Ikeda, Y ;
Umemura, K .
BRAIN RESEARCH, 2001, 902 (01) :30-39
[28]  
INT C HARM ICH E4